鱼跃医疗(002223) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥1,720,240,193.28, representing a 2.21% increase year-over-year, while year-to-date revenue decreased by 9.53% to ¥6,027,852,090.96[2] - Net profit attributable to shareholders for Q3 2024 was ¥411,396,523.81, a decrease of 40.95% compared to the same period last year, and year-to-date net profit decreased by 30.09% to ¥1,531,593,657.16[2] - The basic earnings per share for Q3 2024 was ¥0.4130, down 41.07% year-over-year, with year-to-date earnings per share at ¥1.5374, a decrease of 30.29%[2] - Total operating revenue for the current period is ¥6,027,852,090.96, a decrease of 9.55% compared to ¥6,662,976,651.29 in the previous period[15] - The company's net profit margin is under pressure due to increased sales expenses, which rose to ¥930,620,028.23 from ¥855,049,688.64[15] - The net profit for Q3 2024 was approximately ¥1.53 billion, a decrease of 29.5% compared to ¥2.18 billion in Q3 2023[16] - Operating profit for Q3 2024 was approximately ¥1.75 billion, down 32.8% from ¥2.61 billion in the same period last year[16] - Total comprehensive income for Q3 2024 was approximately ¥1.54 billion, compared to ¥2.18 billion in Q3 2023, indicating a decline of 29.5%[16] Assets and Liabilities - The company's total assets at the end of Q3 2024 were ¥15,494,924,606.69, a decrease of 2.96% from the end of the previous year[2] - The company's cash and cash equivalents decreased to ¥6,682,206,632.31 from ¥7,215,419,322.83, showing a liquidity contraction[12] - Total assets decreased to ¥15,494,924,606.69 from ¥15,967,458,083.34, reflecting a reduction in overall asset base[14] - Total liabilities decreased to ¥2,829,842,688.41 from ¥4,051,960,445.73, indicating a significant reduction in debt levels[14] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥1,382,295,411.79, down 20.85% compared to the previous year[2] - The company's investment activities generated a net cash flow decrease of 93.59% year-over-year, mainly due to the maturity of structured deposits in the previous year[6] - Cash flow from operating activities for Q3 2024 was approximately ¥1.38 billion, a decline of 20.9% compared to ¥1.75 billion in Q3 2023[17] - The company recorded a cash inflow from investment activities of approximately ¥102.30 million in Q3 2024, a significant decrease from ¥1.60 billion in Q3 2023[17] - The company’s operating cash inflow decreased to ¥6.31 billion in Q3 2024 from ¥7.12 billion in Q3 2023, a decline of 11.3%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 43,792, with the largest shareholder, Jiangsu Yuyue Technology Development Co., Ltd., holding 24.54% of the shares[7] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three shareholders alone accounting for 42.58% of the total[9] - The company announced a cash dividend distribution of RMB 4.00 per 10 shares, totaling RMB 400,801,594.80, based on a total share base of 1,002,003,987 shares[11] - The cash dividend distribution will be executed on October 10, 2024, with the record date set for October 9, 2024[11] - Jiangsu Yuyue Medical Equipment Co., Ltd. has a total of 5% or more shareholders, with the largest being China Bank Co., Ltd. holding 2.03%[9] - The company has not reported any changes in the top ten shareholders due to the transfer of shares[9] - The company has not disclosed any related party transactions or agreements among the top shareholders[10] - The total number of preferred shareholders and their holdings has not been applicable for this reporting period[10] - The company has not engaged in any share buyback activities during this reporting period[10] Operational Metrics - Accounts receivable increased by 125.91% compared to the beginning of the period, primarily due to reasonable receivables from normal business operations[5] - The company experienced a 43.02% increase in credit impairment losses year-over-year, attributed to the increase in accounts receivable[5] - Inventory decreased to ¥1,195,113,014.09 from ¥1,412,311,882.61, indicating improved inventory management[12] - Research and development expenses increased to ¥405,052,780.76, compared to ¥397,254,715.93 in the previous period, indicating a continued focus on innovation[15]